Xevudy (sotrovimab)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- sotrovimab
- Company
- GlaxoSmithKline Trading Services Limited
- Status
- Withdrawn
- Therapeutic area
- COVID-19 virus infection
- CHMP opinion
- Thu 16 Dec 2021
- EU approval
- Fri 17 Dec 2021
- Designations
- Additional monitoring
- Application
- EMEA/H/C/005676
- ATC
- J06BD05
- Official record
- www.ema.europa.eu
Indication
Xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID-19.
Regulatory milestones
No milestones recorded in the last year.
Follow Xevudy
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.